The full results of the SURMOUNT-3 trial were published in Nature Medicine and simultaneously presented at ObesityWeek® 2023 INDIANAPOLIS, Oct. 15, 2023 /PRNewswire/ — Detailed results from Eli Lilly and Company’s (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.